These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 10694799)
1. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Weyel D; Sedlacek HH; Müller R; Brüsselbach S Gene Ther; 2000 Feb; 7(3):224-31. PubMed ID: 10694799 [TBL] [Abstract][Full Text] [Related]
2. Gene therapy for sarcoma utilizing adenoviral transfer of the beta-glucuronidase and bax genes and an anthracyline prodrug. Miller SD; Mohiuddin I; Cao XX; Ozvaran MK; Daniel JC; Roy Smythe W J Surg Res; 2004 Oct; 121(2):153-8. PubMed ID: 15501454 [TBL] [Abstract][Full Text] [Related]
3. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Heine D; Müller R; Brüsselbach S Gene Ther; 2001 Jul; 8(13):1005-10. PubMed ID: 11438835 [TBL] [Abstract][Full Text] [Related]
5. Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826). Woessner R; An Z; Li X; Hoffman RM; Dix R; Bitonti A Anticancer Res; 2000; 20(4):2289-96. PubMed ID: 10953287 [TBL] [Abstract][Full Text] [Related]
6. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732 [TBL] [Abstract][Full Text] [Related]
7. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823 [TBL] [Abstract][Full Text] [Related]
8. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate. Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980 [TBL] [Abstract][Full Text] [Related]
9. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483 [TBL] [Abstract][Full Text] [Related]
10. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. Mohr L; Rainov NG; Mohr UG; Wands JR Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203 [TBL] [Abstract][Full Text] [Related]
11. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Roy P; Waxman DJ Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390 [TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828 [TBL] [Abstract][Full Text] [Related]
13. Prodrug activation enzymes in cancer gene therapy. Aghi M; Hochberg F; Breakefield XO J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261 [TBL] [Abstract][Full Text] [Related]
14. Suicide gene therapy using E. coli beta-galactosidase. Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114 [TBL] [Abstract][Full Text] [Related]
15. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Erbs P; Regulier E; Kintz J; Leroy P; Poitevin Y; Exinger F; Jund R; Mehtali M Cancer Res; 2000 Jul; 60(14):3813-22. PubMed ID: 10919655 [TBL] [Abstract][Full Text] [Related]
16. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors. Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390 [TBL] [Abstract][Full Text] [Related]
17. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Chen KC; Cheng TL; Leu YL; Prijovich ZM; Chuang CH; Chen BM; Roffler SR Cancer Gene Ther; 2007 Feb; 14(2):187-200. PubMed ID: 16977328 [TBL] [Abstract][Full Text] [Related]
18. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Schwartz PS; Chen CS; Waxman DJ Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). Leu YL; Roffler SR; Chern JW J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293 [TBL] [Abstract][Full Text] [Related]
20. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]